Small biotech, no approved product or revenue. Pha

Small biotech, no approved product or revenue. Phase 3 testing for PBC (rare disease unlike HIV which isn't so rare), has failed on their 2nd indication for the same drug the NASH was phase 2b it appears, and even after todays plummet. Mkt cap still over 2x of CYDY. Biggest differences(not counting indications just business type vs business type) I can see is number of shares is much lower for CBAY, and they trade on the nasdaq and not the OTC...oh and CYDY doesn't have any failed endpoint indications yet. So CBAY still has that on us. Although NASH seems to be a tough one, so I'm more in for the HIV and cancer. NASH and GvHD would just be icing on the cake.